UK Markets closed

Xvivo Perfusion AB (publ) (0RKL.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
134.00-4.80 (-3.46%)
At close: 05:22PM BST
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.77
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3135.00
52-week low 3131.00
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 526.4M
Implied shares outstanding 6N/A
Float 823.32M
% held by insiders 112.46%
% held by institutions 158.77%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin 7.13%
Operating margin (ttm)1.89%

Management effectiveness

Return on assets (ttm)0.28%
Return on equity (ttm)1.98%

Income statement

Revenue (ttm)327.74M
Revenue per share (ttm)11.21
Quarterly revenue growth (yoy)59.10%
Gross profit (ttm)188.28M
EBITDA 14.72M
Net income avi to common (ttm)23.36M
Diluted EPS (ttm)-1.61
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)317.88M
Total cash per share (mrq)10.75
Total debt (mrq)6.42M
Total debt/equity (mrq)0.48
Current ratio (mrq)6.48
Book value per share (mrq)35.58

Cash flow statement

Operating cash flow (ttm)-19.92M
Levered free cash flow (ttm)-129.94M